Oligodendroglioma medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(39 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Oligodendroglioma}}
{{Oligodendroglioma}}
{{CMG}}{{AE}}{{SR}}
{{CMG}}{{AE}}{{S.M.}}{{SR}}


==Overview==
==Overview==
The predominant [[therapy]] for [[oligodendroglioma]] is [[surgical resection]]. [[Adjuvant chemotherapy|Adjunctive chemotherapy]] and [[radiation]] are required. [[Support|Supportive]] [[therapy]] for [[oligodendroglioma]] includes [[anticonvulsants]] and [[corticosteroids]].


==Medical Therapy==
==Medical Therapy==
The medical therapy of oligodendroglioma includes:
 
'''Innovative treatment options:'''
* [[Brain]] [[tumors]] can be [[Complex (chemistry)|complex]] and require a [[Combination therapy|combination of treatments]] for the [[Best practice|best]] [[outcome|outcome.]]
* There is quite a wide [[Range (statistics)|range]] of [[treatments]] to meet the [[Individual growth|individual]] needs of each [[patient]] which includes [[standard]] [[Therapy|therapies]], [[precision]] [[medicine]] and [[clinical trials]].
* Some of them are listed below:
**'''Brachytherapy:'''
*** Destroys [[tumors]] by [[Implant|implanting]] [[radioactive]] [[medicine]] [[Directly observed treatment|directly]] to or near the [[Treatments|treatment]] site.
** '''Chemotherapy:'''
*** [[Reachback|Reaches]] [[cancer]] that may have [[Spreading activation|spread]], even [[Microscopic|microscopically]], throughout the [[Human body|body]].
** '''Craniotomy:'''
*** [[Surgical procedure]] that removes a [[bone]] flap, a [[section]] of the [[skull]], to [[Accessibility|access]] the [[brain]].
** '''Intensity-modulated radiation therapy:'''
*** Uses [[Computer-assisted|computer]] technology to [[Delivery|deliver]] [[radiation treatment]] that precisely [[fits]] the [[Size consistency|size]] and [[Shape parameter|shape]] of the [[tumor]].
** '''Minimally invasive cranial base surgery:'''
*** Uses smaller [[Incision|incisions]] and specially [[Design matrix|designed]] [[Instrumental variable|instruments]] to eliminate a [[tumor]] while saving the surrounding [[tissue]] from damage.
** '''Stereotactic radiosurgery & radiotherapy:'''
*** A [[noninvasive]] [[procedure]] that applies [[Large-print|large]] [[doses]] of [[radiation]] [[Directly observed treatment|directly]] to a [[tumor]].
The [[Medical therapy template|medical therapy]] for [[oligodendroglioma]] includes:


===Radiotherapy===
===Radiotherapy===
*[[Radiation|Post-operative radiotherapy]] is recommended among all patients who develop oligodendroglioma.<ref name=rx>Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref>
*[[Radiation|Post-operative radiotherapy]] is recommended among all [[patients]] who [[Development|develop]] [[oligodendroglioma|oligodendroglioma.]]<ref name="rx">Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref><ref name="pmid30988626">{{cite journal| author=Harat M, Blok M, Harat A, Soszyńska K| title=The impact of adjuvant radiotherapy on molecular prognostic markers in gliomas. | journal=Onco Targets Ther | year= 2019 | volume= 12 | issue=  | pages= 2215-2224 | pmid=30988626 | doi=10.2147/OTT.S200818 | pmc=6441459 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30988626  }} </ref>
*Radiotherapy may not cure the cancer but can control the tumor, delay recurrence, and increase survival.
*[[Radiotherapy]] may not [[cure]] the [[cancer]] but it can:
*[[Radiation|External beam radiation therapy]] is preferred to whole brain radiotherapy.<ref name=rx>Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref>
**[[Control]] the [[tumor]]
**Delay [[Recurrence plot|recurrence]]
**Increase [[Survival analysis|survival]]
*[[Radiation|External beam radiation therapy]] is [[Preferences|preferred]] to whole [[brain]] [[radiotherapy|radiotherapy.]]<ref name="rx">Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref>
*[[External beam radiation therapy]] is usually administered in [[standard]] [[Fraction (chemistry)|fractions]] of 1.8–2 Gy and can [[Reachback|reach]] a total [[dose]] of 60 Gy.<ref name="pmid20555079">{{cite journal| author=Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group| title=High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | journal=Ann Oncol | year= 2010 | volume= 21 Suppl 5 | issue=  | pages= v190-3 | pmid=20555079 | doi=10.1093/annonc/mdq187 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20555079  }} </ref>


===Chemotherapy===
===Chemotherapy===
*[[Chemotherapy]] is indicated as adjuvant therapy for oligodendroglioma.<ref name=rx>Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref>
*[[Chemotherapy]] is [[Indication (medicine)|indicated]] as [[adjuvant therapy]] for [[oligodendroglioma|oligodendroglioma.]]<ref name="rx">Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref><ref name="pmid9776413">{{cite journal| author=Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR et al.| title=Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. | journal=J Natl Cancer Inst | year= 1998 | volume= 90 | issue= 19 | pages= 1473-9 | pmid=9776413 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9776413  }} </ref><ref name="pmid23071247">{{cite journal| author=Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J et al.| title=Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. | journal=J Clin Oncol | year= 2013 | volume= 31 | issue= 3 | pages= 337-43 | pmid=23071247 | doi=10.1200/JCO.2012.43.2674 | pmc=3732012 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23071247  }} </ref><ref name="pmid23071237">{{cite journal| author=van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY et al.| title=Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. | journal=J Clin Oncol | year= 2013 | volume= 31 | issue= 3 | pages= 344-50 | pmid=23071237 | doi=10.1200/JCO.2012.43.2229 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23071237  }} </ref><ref name="pmid28263309">{{cite journal| author=Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I et al.| title=EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. | journal=Nat Med | year= 2017 | volume= 23 | issue= 4 | pages= 483-492 | pmid=28263309 | doi=10.1038/nm.4293 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28263309  }} </ref>
*Oligodendroglioma responds better to chemotherapy than astrocytoma of comparable grade.<ref name="pmiddoi:10.1016/S0090-3019(03)00167-8">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=doi:10.1016/S0090-3019(03)00167-8 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10  }} </ref>
*[[Oligodendroglioma]] responds better to [[chemotherapy]] than [[astrocytoma]] of [[Comparability|comparable]] [[Grading (tumors)|grade.]]<ref name="pmiddoi:10.1016/S0090-3019(03)00167-8">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=doi:10.1016/S0090-3019(03)00167-8 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10  }} </ref>
*Oligodendroglioma is the most chemosensitive of all the [[glioma|glial tumors]].<ref name="pmid3382171">{{cite journal| author=Cairncross JG, Macdonald DR| title=Successful chemotherapy for recurrent malignant oligodendroglioma. | journal=Ann Neurol | year= 1988 | volume= 23 | issue= 4 | pages= 360-4 | pmid=3382171 | doi=10.1002/ana.410230408 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3382171  }} </ref>
*[[Oligodendroglioma]] is the most chemosensitive of all the [[glioma|glial tumors.]]<ref name="pmid3382171">{{cite journal| author=Cairncross JG, Macdonald DR| title=Successful chemotherapy for recurrent malignant oligodendroglioma. | journal=Ann Neurol | year= 1988 | volume= 23 | issue= 4 | pages= 360-4 | pmid=3382171 | doi=10.1002/ana.410230408 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3382171 }} </ref>
*[[Temozolomide]] ([[Temodar]]) is the preferred drug for the treatment of oligodendroglioma.<ref name=rx>Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref>
*[[Symptomatic]], aggressive, enlarging, [[Enhancer (genetics)|enhancing]], and non-[[anaplastic]] [[oligodendrogliomas]] respond better to [[chemotherapy|chemotherapy.]]<ref name="pmid1641113">{{cite journal| author=Cairncross JG, Macdonald DR, Ramsay DA| title=Aggressive oligodendroglioma: a chemosensitive tumor. | journal=Neurosurgery | year= 1992 | volume= 31 | issue= 1 | pages= 78-82 | pmid=1641113 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1641113 }} </ref>
*[[PCV regimen|PCV 3 combination chemotherapy]] is the preferred drug regimen for oligodendroglioma.<ref name=rx>Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref>
*[[Temozolomide]] ([[Temodar]]) is the [[Preferences|preferred]] [[drug]] for the [[Treatments|treatment]] of [[oligodendroglioma|oligodendroglioma.]]<ref name="rx">Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref>
**[[CCNU]] is administered on day 1, [[procarbazine]] is administered daily for 14 days beginning on day 8, and [[vincristine]] is administered on days 8 and 29 of each 6-week cycle of therapy.<ref name="pmid7407756">{{cite journal| author=Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ et al.| title=Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. | journal=Cancer Treat Rep | year= 1980 | volume= 64 | issue= 2-3 | pages= 237-44 | pmid=7407756 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7407756  }} </ref>
*[[PCV regimen|PCV 3 regimen]] is the [[Preferences|preferred]] [[Combination therapy|combination]] [[chemotherapy]] for [[anaplastic|anaplastic oligodendroglioma]] which includes the following [[dosing]] [[Schedule I|schedule]]:<ref name="rx">Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref><ref name="pmid12107116">{{cite journal| author=Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J et al.| title=Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. | journal=Am J Pathol | year= 2002 | volume= 161 | issue= 1 | pages= 313-9 | pmid=12107116 | doi=10.1016/S0002-9440(10)64183-1 | pmc=PMC1850690 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12107116  }} </ref>
*Other chemotherapeutic drugs that may be used for the treatment of oligodendroglioma include:<ref name=rxchemo>Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on</ref><ref name="pmid3382171">{{cite journal| author=Cairncross JG, Macdonald DR| title=Successful chemotherapy for recurrent malignant oligodendroglioma. | journal=Ann Neurol | year= 1988 | volume= 23 | issue= 4 | pages= 360-4 | pmid=3382171 | doi=10.1002/ana.410230408 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3382171  }} </ref>
**[[CCNU]] is administered on day 1
**[[Procarbazine]] is administered [[Daily Med|daily]] for 14 days beginning on day 8
**[[Vincristine]] is administered on days 8 and 29 of each 6-week [[Cycle (gene)|cycle]] of [[therapy]]<ref name="pmid7407756">{{cite journal| author=Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ et al.| title=Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. | journal=Cancer Treat Rep | year= 1980 | volume= 64 | issue= 2-3 | pages= 237-44 | pmid=7407756 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7407756  }} </ref>
*Other [[Chemotherapeutic agent|chemotherapeutic drugs]] that may be used for the [[Treatments|treatment]] of [[oligodendroglioma]] include:<ref name="rxchemo">Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on</ref><ref name="pmid3382171">{{cite journal| author=Cairncross JG, Macdonald DR| title=Successful chemotherapy for recurrent malignant oligodendroglioma. | journal=Ann Neurol | year= 1988 | volume= 23 | issue= 4 | pages= 360-4 | pmid=3382171 | doi=10.1002/ana.410230408 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3382171  }} </ref>
**[[Carmustine]]
**[[Carmustine]]
**[[Cisplatin]]
**[[Cisplatin]]
Line 29: Line 54:
**[[Methotrexate]] ([[intrathecal|intrathecally]])
**[[Methotrexate]] ([[intrathecal|intrathecally]])
**Diaziquone
**Diaziquone
*If oligodendroglioma is unresponsive to the chemotherapeutic drugs used in earlier treatments or if it recurs, other drugs that may be used include:<ref name=rxchemo>Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on</ref>
*If [[oligodendroglioma]] is [[unresponsive]] to the [[Chemotherapeutic agent|chemotherapeutic drugs]] used in earlier [[treatments]] or if it [[Recurrence plot|recurs]], other [[drugs]] that may be used include:<ref name="rxchemo">Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on</ref>
**[[Tamoxifen]]  
**[[Tamoxifen]]
**[[Carboplatin]]
**[[Carboplatin]]
**[[Etoposide]]
**[[Etoposide]]


===Supportive treatment===
===Supportive treatment===
*Supportive therapy for oligodendroglioma includes [[anticonvulsants]] and [[corticosteroids]], which focuses on relieving symptoms and improving the patient’s neurologic function.<ref name=rx>Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on</ref>
*[[Support|Supportive]] [[therapy]] for [[oligodendroglioma]] [[Focusing|focuses]] on relieving [[symptoms]] and [[Improving agent|improving]] the [[Patient|patient’s]] [[Neurological|neurologic]] [[Function (biology)|function]] and includes:<ref name="rx" />
**[[Anticonvulsants]] are administered to the patients who have a [[seizure]]. [[Phenytoin]] given concurrently with [[radiation]] may have serious skin reactions such as [[erythema multiforme]] and [[Stevens-Johnson syndrome]].
*[[Anticonvulsants]]:
**[[Corticosteroids]], usually [[dexamethasone]] given 4-10 mg every 4-6 h, can reduce peritumoral [[edema]], diminish mass effect, and lower [[intracranial pressure]] with a decrease in symptoms ([[headache]] or [[drowsiness]]).
**[[Anticonvulsants]] are administered to the [[patients]] who have a [[seizure]]
**[[Phenytoin]] given [[Concurrent overlap|concurrently]] with [[radiation]] may have [[Serious adverse event|serious]] [[skin]] [[Reactions on surfaces|reactions]] such as:
***[[Erythema multiforme]]
***[[Stevens-Johnson syndrome]]
*[[Corticosteroids]]:
**Usually [[dexamethasone]] is given 4-10 mg every 4-6 h, which [[Lead|leads]] to:
***[[Reduced]] peritumoral [[edema]]
***Diminished [[mass effect]]
***Lower [[intracranial pressure]] with a decrease in [[symptoms]] ([[headache]] or [[drowsiness]])


==References==
==References==
Line 50: Line 83:
[[Category:Disease]]
[[Category:Disease]]
[[Category:Mature chapter]]
[[Category:Mature chapter]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Neurology]]
[[Category:Neurosurgery]]

Latest revision as of 14:23, 13 August 2019

Oligodendroglioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Oligodendroglioma from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Staging

History & Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Oligodendroglioma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Oligodendroglioma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Oligodendroglioma medical therapy

CDC on Oligodendroglioma medical therapy

Oligodendroglioma medical therapy in the news

Blogs on Oligodendroglioma medical therapy

Directions to Hospitals Treating Oligodendroglioma

Risk calculators and risk factors for Oligodendroglioma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]

Overview

The predominant therapy for oligodendroglioma is surgical resection. Adjunctive chemotherapy and radiation are required. Supportive therapy for oligodendroglioma includes anticonvulsants and corticosteroids.

Medical Therapy

Innovative treatment options:

The medical therapy for oligodendroglioma includes:

Radiotherapy

Chemotherapy

Supportive treatment

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Treatment of oligodendroglioma. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/brain-and-spinal-tumours/oligodendroglioma/?region=on
  2. ↑ Harat M, Blok M, Harat A, Soszyńska K (2019). "The impact of adjuvant radiotherapy on molecular prognostic markers in gliomas". Onco Targets Ther. 12: 2215–2224. doi:10.2147/OTT.S200818. PMC 6441459. PMID 30988626.
  3. ↑ Stupp R, Tonn JC, Brada M, Pentheroudakis G, ESMO Guidelines Working Group (2010). "High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann Oncol. 21 Suppl 5: v190–3. doi:10.1093/annonc/mdq187. PMID 20555079.
  4. ↑ Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR; et al. (1998). "Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas". J Natl Cancer Inst. 90 (19): 1473–9. PMID 9776413.
  5. ↑ Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J; et al. (2013). "Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402". J Clin Oncol. 31 (3): 337–43. doi:10.1200/JCO.2012.43.2674. PMC 3732012. PMID 23071247.
  6. ↑ van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY; et al. (2013). "Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951". J Clin Oncol. 31 (3): 344–50. doi:10.1200/JCO.2012.43.2229. PMID 23071237.
  7. ↑ Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I; et al. (2017). "EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas". Nat Med. 23 (4): 483–492. doi:10.1038/nm.4293. PMID 28263309.
  8. ↑ Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID doi:10.1016/S0090-3019(03)00167-8 Check |pmid= value (help).
  9. ↑ 9.0 9.1 Cairncross JG, Macdonald DR (1988). "Successful chemotherapy for recurrent malignant oligodendroglioma". Ann Neurol. 23 (4): 360–4. doi:10.1002/ana.410230408. PMID 3382171.
  10. ↑ Cairncross JG, Macdonald DR, Ramsay DA (1992). "Aggressive oligodendroglioma: a chemosensitive tumor". Neurosurgery. 31 (1): 78–82. PMID 1641113.
  11. ↑ Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J; et al. (2002). "Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets". Am J Pathol. 161 (1): 313–9. doi:10.1016/S0002-9440(10)64183-1. PMC 1850690. PMID 12107116.
  12. ↑ Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ; et al. (1980). "Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors". Cancer Treat Rep. 64 (2–3): 237–44. PMID 7407756.
  13. ↑ 13.0 13.1 Chemotherapeutic drugs in malignant gliomas. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/treatment/chemotherapy/?region=on


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Oligodendroglioma_medical_therapy&oldid=1579132"